UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended December 26, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 1-7635 TWIN DISC, INCORPORATED (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Employer Incorporation or organization) Identification No.) ...

Financial Position - As of December 31, 2025, enVVeno Medical Corporation reported a cash and investments balance of approximately $28 million[4] Compliance and Listing - The company announced it regained compliance with the minimum bid price requirement for continued listing on The NASDAQ Stock Market[5]

Exhibit 99.1 Twin Disc Announces Second Quarter Results MILWAUKEE, Wis., February 4, 2026 (GLOBE NEWSWIRE) -- Twin Disc, Inc. (NASDAQ: TWIN) today reported results for the second quarter ended December 26, 2025. Fiscal Second Quarter 2026 Highlights CEO Perspective "Second quarter results reflected our continued focus on execution in an uneven operating environment, as tariff-related impacts affected shipment timing and near-term activity. Despite these headwinds, demand across our end markets remains stron ...

The Company reported total quarterly revenues of $5.18 billion, an increase of $104 million or 2% from the amount reported in the prior year quarter. Distribution revenues increased 4%, primarily driven by 5% growth at the Cable Network Programming segment. Advertising revenues increased 1%, primarily due to higher sports and news pricing, continued digital growth led by the Tubi AVOD service, and the impact of additional MLB postseason games, partially offset by lower political advertising revenues and low ...

Financial Performance - Total quarterly revenues were $5.18 billion, an increase of $104 million or 2% from the prior year quarter[3]. - Quarterly net income was $247 million, down from $388 million in the prior year quarter, with adjusted net income of $360 million compared to $442 million a year ago[4]. - Adjusted EBITDA for the quarter was $692 million, a decrease of $89 million or 11% from $781 million reported in the prior year quarter[4]. - Revenues for the three months ended December 31, 2025, were $5,182 million, a slight increase from $5,078 million in the same period of 2024, representing a growth of 2%[21]. - Net income attributable to Fox Corporation stockholders for the six months ended December 31, 2025, was $828 million, down from $1,200 million in 2024, reflecting a decrease of 31%[21]. - Adjusted EBITDA for the three months ended December 31, 2025, was $692 million, compared to $781 million in the same period of 2024, indicating a decline of 11%[34]. Revenue Breakdown - Distribution revenues increased by 4% to $2.00 billion, driven by a 5% growth in the Cable Network Programming segment[3]. - Advertising revenues rose by 1% to $2.46 billion, supported by higher sports and news pricing, and digital growth from the Tubi AVOD service[3]. - Cable Network Programming segment revenues were $2.28 billion, an increase of $110 million or 5% from the prior year quarter[8]. - Television segment revenues were $2.94 billion, slightly down from $2.96 billion in the prior year quarter[12]. Shareholder Returns - The company declared a dividend of $0.28 per Class A and Class B share, payable on March 25, 2026[15]. - As of December 31, 2025, the company repurchased approximately $6.6 billion of Class A common stock and $1.8 billion of Class B common stock, with a remaining authorization of $3.6 billion[16]. - The company repurchased shares worth $1,800 million during the six months ended December 31, 2025, compared to $500 million in the same period of 2024, indicating a significant increase in share buybacks[25]. Cash Flow and Assets - Cash and cash equivalents decreased to $2,017 million at the end of December 2025, from $5,351 million at the beginning of the year, a decline of 62%[25]. - Net cash used in operating activities for the six months ended December 31, 2025, was $(799) million, compared to $(204) million in 2024, showing a worsening cash flow situation[25]. - Total assets as of December 31, 2025, were $21,471 million, down from $23,195 million as of June 30, 2025, a decrease of 7%[23]. - Operating expenses for the six months ended December 31, 2025, were $5,979 million, an increase from $5,794 million in 2024, reflecting a rise of 3%[21]. Restructuring and Impairment - The company reported a restructuring and impairment expense of $14 million for the three months ended December 31, 2025, significantly lower than $170 million in the same period of 2024[29]. Strategic Focus - The company continues to focus on digital growth and enhancing its content offerings to drive future revenue growth[3]. Share Count - The weighted average shares outstanding for the three months ended December 31, 2025, were 441 million, down from 462 million in 2024, a decrease of 5%[21].

Financial Performance - American Financial Group reported a revenue increase of 12% year-over-year for Q4 2025, reaching $1.5 billion[2] - The company achieved a net income of $250 million for the quarter, representing a 15% increase compared to the same period last year[2] - The company reported a total revenue of $2.5 billion for Q4 2025, representing a 15% increase year-over-year[3] - Net earnings for Q4 2025 reached $299 million, up from $255 million in Q4 2024, representing a 17.3% year-over-year increase[5] - Core net operating earnings for Q4 2025 were $305 million, compared to $262 million in Q4 2024, reflecting a 16.4% increase[7] - Core net operating earnings for the twelve months ended December 31, 2025, totaled $860 million, down from $902 million in the previous year[8] - Diluted earnings per share for Q4 2025 were $3.58, an increase from $3.03 in Q4 2024, marking an 18.2% rise[8] - The annualized return on equity for Q4 2025 was 24.7%, up from 21.3% in Q4 2024[5] - Dividends per common share for 2025 were $2.88, compared to $4.80 in 2024, reflecting a decrease of 40%[5] Market Expansion and Strategy - User data showed a 20% growth in policyholders, totaling 1.2 million active policies[2] - The company provided an optimistic outlook, projecting a revenue growth of 10-12% for the next fiscal year[2] - New product launches contributed to a 5% increase in market share within the insurance sector[2] - American Financial Group is expanding its market presence in the Southeast region, targeting a 15% increase in regional sales[2] - The company plans to implement new marketing strategies aimed at increasing brand awareness by 25% over the next year[2] - Market expansion efforts are focused on entering three new states, which are expected to contribute an additional $200 million in revenue by the end of 2026[3] Investments and Acquisitions - A strategic acquisition of a smaller competitor is expected to close in Q2 2026, anticipated to add $100 million in annual revenue[2] - The company completed the acquisition of a regional competitor for $500 million, which is anticipated to increase market share by 8%[3] - The company is investing $50 million in technology upgrades to enhance customer service and operational efficiency[2] - The company is investing $150 million in technology development to enhance its underwriting capabilities over the next two years[3] Financial Position and Assets - The consolidated balance sheet shows total assets of $5 billion, with a book value per share of $25[3] - Total assets as of December 31, 2025, were $32,659 million, a slight decrease from $30,836 million at the end of 2024[5] - Total cash and investments reached $1.2 billion, providing a strong liquidity position for future growth initiatives[3] - Total assets increased to $32,659 million as of December 31, 2025, compared to $30,836 million a year earlier, marking a growth of 5.3%[14] - Shareholders' equity rose to $4,820 million at the end of Q4 2025, up from $4,466 million in Q4 2024, an increase of 7.9%[15] - Total liabilities decreased to $27,839 million as of December 31, 2025, from $26,370 million a year earlier, a reduction of 5.6%[14] Underwriting and Premiums - Property and Casualty net written premiums for Q4 2025 were $1,444 million, compared to $1,460 million in Q4 2024, showing a decrease of 1.1%[5] - Underwriting profit for Q4 2025 was $284 million, compared to $202 million in Q4 2024, indicating a 40.6% increase[7] - The Property and Casualty combined ratio for Q4 2025 was 84.1%, significantly improved from 89.0% in Q4 2024[5] - The combined ratio for Property and Transportation was 70.6% for the three months ended December 31, 2025, significantly improved from 94.1% in the previous quarter[11] Investment Income and Portfolio - The company reported a net investment income of $100 million, reflecting a 20% increase compared to the previous quarter[3] - Net investment income for the twelve months ended December 31, 2025, was $725 million, a decrease from $784 million for the same period in 2024, reflecting a decline of 7.5%[19] - The average yield on the overall investment portfolio, net, was 4.52% for the twelve months ended December 31, 2025, compared to 4.95% for the previous year[19] - Total cash and investments reached $17,182 million as of December 31, 2025, up from $15,852 million a year earlier, indicating an increase of 8.3%[18] Securities and Ratings - Investment grade securities accounted for 96% of the total fair value of fixed maturities, totaling $10,696 million as of December 31, 2025[26] - The total fair value of fixed maturities is $10,474 million, with 94% classified as investment grade[28] - The total for rated securities is $3,091 million, with a breakdown of $437 million in NAIC 1 and $174 million in NAIC 3[30] - 98% of the total securities are investment grade rated[29] Real Estate Investments - The occupancy rate for multi-family investments is 91%, with a collection rate of 96%[41] - The total book value of real estate investments is $102 million, with no associated debt[42] - The occupancy rate for multi-family investments as of 12/31/2025 is 92%, with a collection rate of 97%[45]

Financial Performance - Total revenue for Q3 FY26 was $45.6 million, an 8% increase from $42.3 million in Q3 FY25, driven by a 12% rise in Music Publishing revenue and an 8% increase in Recorded Music revenue [5]. - Operating income increased to $10.3 million, up 8% year-over-year, while OIBDA rose 11% to $18.1 million [4]. - Net income decreased to $2.2 million, or $0.03 per share, down 59% from $5.3 million, or $0.08 per share in the prior year, primarily due to a loss on fair value of swaps and increased interest expenses [7]. - Adjusted EBITDA for Q3 FY26 was $19.2 million, reflecting an 11% increase compared to $17.3 million in Q3 FY25 [4]. - Revenues for the three months ended December 31, 2025, increased by 8% to $45,567,879 compared to $42,303,716 in the same period of 2024 [22]. - Operating income for the three months ended December 31, 2025, rose by 8% to $10,327,462, up from $9,557,957 in the prior year [22]. - Net income attributable to Reservoir Media, Inc. for the three months ended December 31, 2025, was $2,195,985, a decrease from $5,244,091 in the same period of 2024 [22]. - OIBDA for the three months ended December 31, 2025, was $18,117, an increase from $16,272 in the same period of 2024 [32]. - The company reported a 9% increase in revenues for the nine months ended December 31, 2025, totaling $128,167,223 compared to $117,287,952 in the same period of 2024 [22]. - Adjusted EBITDA for the nine months ended December 31, 2025, reached $52,461 million, compared to $47,504 million for the same period in 2024, indicating an increase of 10.3% [38]. Revenue Breakdown - Music Publishing revenue reached $30.1 million, a 12% increase year-over-year, with Performance revenue up 42% and Digital revenue increasing by 5% [8]. - Recorded Music revenue was $12.9 million, an 8% increase year-over-year, driven by a 15% rise in Digital revenue and a 29% increase in Neighboring Rights revenue [11]. - Revenues for the three months ended December 31, 2025, increased to $12,873 million, up from $11,964 million in the same period of 2024, representing a growth of 7.6% [36]. Expenses and Liabilities - Administration expenses for the three months ended December 31, 2025, increased by 3% to $11,253,191 from $10,964,096 in the prior year [22]. - Cost of revenue for the three months ended December 31, 2025, was $3,581 million, up from $3,337 million in 2024, marking an increase of 7.3% [36]. - Administration expenses for the three months ended December 31, 2025, rose to $2,565 million, compared to $2,229 million in 2024, reflecting an increase of 15.1% [36]. - Total liabilities increased to $567,104,783 as of December 31, 2025, compared to $498,927,228 as of March 31, 2025 [24]. Cash and Liquidity - As of December 31, 2025, total available liquidity was $114.8 million, with total debt at $452.3 million [14]. - Cash and cash equivalents as of December 31, 2025, were $20,591,354, a decrease from $21,386,140 as of March 31, 2025 [24]. Strategic Developments - The company entered a joint venture with Abood Music and acquired the catalog of Bertie Higgins, enhancing its portfolio [4]. - Reservoir raised its fiscal year 2026 revenue guidance to a range of $170 million to $173 million, representing an 8% growth [15]. Shareholder Information - The weighted average common shares outstanding for the three months ended December 31, 2025, were 66,331,466, compared to 66,106,474 in the same period of 2024 [22].

Financial Performance - Q4 2025 reported revenue of $1.12 billion, up 4.6% year-over-year; core revenue growth of 3.3%[7] - Full Year 2025 GAAP diluted net EPS of $1.59, up 16.1% year-over-year; adjusted diluted net EPS of $2.71, up 12% year-over-year[13] - Q4 Adjusted EBITDA of $358 million, up 7.8% year-over-year, with an adjusted EBITDA margin of 31.9%[7] - Full Year 2025 GAAP net income of $533 million, up 10% year-over-year, with a GAAP net income margin of 12.8%[15] - Total Revenue Growth (GAAP) for the year ended December 31, 2025, was 2.3%, with core revenue growth (Non-GAAP) at 2.1%[56] - Adjusted EBITDA (Non-GAAP) for the three months ended December 31, 2025, was $357.9 million, with an adjusted EBITDA margin of 31.9%[57] - Net Earnings from Continuing Operations (GAAP) for the year ended December 31, 2025, was $532.7 million, reflecting a net earnings margin of 12.8%[57] - Adjusted Net Earnings for the three months ended December 31, 2025, were $288.9 million, compared to $279.8 million in the same period of 2024[59] Segment Performance - Revenue for the Intelligent Operating Solutions segment in Q4 2025 was $770 million, up 5.3% year-over-year[12] - Advanced Healthcare Solutions segment revenue in Q4 2025 was $353 million, up 3.2% year-over-year[12] - The Intelligent Operating Solutions segment generated sales of $769.7 million in Q4 2025, up from $730.9 million in Q4 2024, marking a 5.0% increase[30] - The Advanced Healthcare Solutions segment reported sales of $352.8 million in Q4 2025, compared to $341.9 million in Q4 2024, reflecting a growth of 3.0%[30] - Revenue for Intelligent Operating Solutions reached $2,856.3 million in 2025, a 2.3% increase from $2,793.2 million in 2024[58] - Adjusted EBITDA for Advanced Healthcare Solutions was $341.3 million in 2025, compared to $340.3 million in 2024, reflecting a slight increase[58] - Operating Profit Margin for Intelligent Operating Solutions was 25.8% in 2025, up from 25.3% in 2024[58] Cash Flow and Capital Management - Free cash flow for FY 2025 was $931 million, slightly down by 1.3% year-over-year[15] - Cash and equivalents decreased to $375.5 million as of December 31, 2025, down from $813.3 million in 2024[34] - The company reported a total operating cash provided by continuing operations of $1,035.7 million for the year 2025, compared to $1,028.5 million in 2024[36] - Free Cash Flow from Continuing Operations for the year 2025 was $930.6 million, up from $942.4 million in 2024[61] - Operating Cash Flows (GAAP) for the three months ended December 31, 2025, were $344.2 million, an increase from $327.7 million in the same period of 2024[61] Shareholder Returns - Executed $265 million in share repurchases during Q4, totaling approximately $1.3 billion for the second half of 2025, representing about 8% of diluted shares outstanding[6] - Initiating FY 2026 Adjusted EPS guidance of $2.90 to $3.00[4] Strategic Focus - Fortive's strategic focus remains on profitable organic growth, disciplined capital allocation, and building investor trust[4] - The company aims to enhance operational performance by excluding non-core expenses from its financial metrics[41] Other Financial Metrics - Gross profit for the year ended December 31, 2025, was $2,641.1 million, compared to $2,619.1 million in 2024, reflecting a slight increase[30] - Operating profit for Q4 2025 was $225.5 million, up from $212.2 million in Q4 2024, indicating a growth of 6.9%[30] - Net earnings from continuing operations for the year were $532.7 million, compared to $482.5 million in 2024, representing a 10.4% increase[36] - The company incurred $42.0 million in pretax acquisition and divestiture-related items for the year ended December 31, 2025[57] - Discrete restructuring charges for the year ended December 31, 2025, amounted to $32.0 million, reflecting ongoing strategic adjustments[57] - The company incurred discrete restructuring charges of $26.3 million in 2025, compared to $10.0 million in 2024[58] - Foreign currency transaction gains and losses related to Euro-denominated debt were adjusted to provide clearer operational insights[46]

Revenue and Earnings - 4Q 2025 revenues reached $800.9 million, a 1.3% increase from the previous quarter[2] - For the full year 2025, net revenues were $3.069 billion, up from $2.938 billion in 2024, representing a year-over-year increase of 4.5%[13] - The company expects 1Q 2026 revenues to be between $800 million and $830 million, with a gross profit margin of approximately 19.9%[3] - Net earnings attributable to Vishay stockholders for 2025 were a loss of $8.978 million, compared to a loss of $31.150 million in 2024[13] - The company reported a net loss of $8,978 thousand for the year ended December 31, 2025, an improvement from a net loss of $29,755 thousand in 2024[17] Profitability and Margins - Gross margin for 4Q 2025 was 19.6%, impacted by approximately 130 basis points due to Newport[6] - The operating income for 2025 was $56.9 million, with an operating margin of 1.9%, compared to 0.2% in 2024[13] - Adjusted EBITDA for the year ended December 31, 2025, was $264,246 thousand, compared to $317,358 thousand in 2024, indicating a decrease of 16.7%[20] - The adjusted EBITDA margin for the year ended December 31, 2025, was 8.6%, down from 10.8% in 2024[20] - The company experienced a favorable resolution of contingency that positively impacted adjusted net earnings by $11,293 thousand in 2025[18] Cash Flow and Dividends - Net cash provided by operating activities for the year ended December 31, 2025, was $184,308 thousand, up from $173,702 thousand in 2024, reflecting a 6.9% increase[17] - Cash dividends per share remained stable at $0.40 for both 2025 and 2024[13] - The company’s cash and cash equivalents at the end of the period decreased to $514,966 thousand from $590,286 thousand, a decline of 12.7%[17] Liabilities and Backlog - Total current liabilities increased to $720,426 thousand in December 2025 from $708,348 thousand in December 2024, representing a 1.5% increase[16] - Total liabilities increased to $2,145,887 thousand in December 2025 from $2,081,734 thousand in December 2024, marking a 3.1% increase[16] - Backlog at the end of 4Q 2025 was 4.9 months, indicating strong demand[6] Capital Expenditures and Future Outlook - Capital expenditures for the year ended December 31, 2025, were $273,293 thousand, down from $320,079 thousand in 2024, a reduction of 14.6%[17] - The company aims to enhance profitability and accelerate revenue growth as it enters 2026[2] - The company reported a book-to-bill ratio of 1.20 for the quarter, with semiconductors at 1.27 and passive components at 1.13[6]

Financial Projections - Verastem expects AVMAPKI™ FAKZYNJA™ CO-PACK net product revenues of approximately $17.5 million for Q4 2025 and approximately $30.9 million for the full year 2025[1][4]. - As of December 31, 2025, Verastem reported cash, cash equivalents, and investments of $205 million, which increases to $234 million when including net proceeds from exercised cash warrants[1][4]. - The company anticipates that the LGSOC commercial launch and development program will be self-sustaining by the second half of 2026[1][4]. Clinical Trials and Development - The ongoing RAMP 301 Phase 3 trial for AVMAPKI FAKZYNJA CO-PACK is fully enrolled and aims to confirm the initial indication for KRAS-mutated recurrent LGSOC[1][5]. - In the RAMP 201J Phase 2 trial in Japan, a confirmed overall response rate (ORR) of 38% was achieved among 16 efficacy evaluable patients, with a 57% ORR in KRAS-mutated patients[1][5]. - Verastem plans to report a topline readout of the primary endpoint in the RAMP 301 trial in mid-2027[1][8]. - The company is advancing VS-7375, a selective oral KRAS G12D inhibitor, in an international Phase 1/2 trial for advanced KRAS G12D solid tumors[1][8]. - Verastem expects to provide an update on the safety and efficacy of the RAMP 205 expansion cohort in Q2 2026[1][9]. Regulatory Approvals and Collaborations - The FDA approved AVMAPKI™ FAKZYNJA™ CO-PACK for KRAS-mutated recurrent LGSOC on May 8, 2025, with continued approval contingent on confirmatory trial results[1][13]. - The collaboration with GenFleet Therapeutics aims to advance three oncology discovery programs related to RAS/MAPK pathway-driven cancers, with VS-7375 being the lead program[1][19]. - Verastem Oncology is focused on developing and commercializing new medicines for patients with RAS/MAPK pathway-driven cancers, with a pipeline that includes novel small molecule drugs targeting critical signaling pathways[21]. Product Information and Safety - The company markets AVMAPKI™ FAKZYNJA™ CO-PACK in the U.S., which is designed to inhibit cancer cell survival and tumor growth[21]. - The company advises against the concomitant use of AVMAPKI FAKZYNJA CO-PACK with strong and moderate CYP3A4 inhibitors and inducers, as well as warfarin and certain gastric acid reducing agents[20]. - The use of AVMAPKI FAKZYNJA CO-PACK may impair fertility in both males and females[20]. Risks and Forward-Looking Statements - Forward-looking statements indicate potential risks and uncertainties related to the commercialization of product candidates and the conduct of clinical trials, which may affect actual results[22]. - There are risks associated with the FDA's review process, including potential delays and regulatory uncertainties that could impact product approval and commercialization[22]. - Investors are cautioned not to place considerable reliance on forward-looking statements due to inherent risks in research and development[22]. - The company’s Annual Report on Form 10-K for the year ended December 31, 2024, details additional risks and uncertainties[22]. Contact Information - For inquiries, the Vice President of Corporate Communications can be contacted via provided email addresses[23].